Qiang Huo

Laboratory molecular survey of the Chinese herbal medicine market, not a clinical study. An ITS2 mini-barcode reference matrix was built for genuine Notopterygii Rhizoma et Radix and its known adulterants, and 120 successfully amplified market samples were genotyped; ITS2 gave 100 percent species-level identification by both BLASTN and neighbour-joining methods. Levisticum officinale was the most widely sold adulterant (markets in nine provinces), followed by N. oviforme (eight), Angelica amurensis (six) and Ostericum scaberulum (two), with Heracleum fargesii, Haplosphaera himalayensis and Broussonetia papyrifera also detected. N. incisum accounted for about two-thirds of the authentic material found. This is the primary evidence that Qiang Huo bought without authentication is often not Qiang Huo.

Human enzyme study of notopterol, the principal constituent of Notopterygium incisum and N. forbesii. Notopterol inhibited CYP2D6 in a time-, concentration- and NADPH-dependent manner with KI 10.8 microM and kinact 0.62 per minute; kobs at 10 microM was 0.29 per minute, more than ten times the 0.02 per minute risk threshold, and about 92 percent of activity was lost after 9 minutes. Inhibition was not reversed by dialysis, quinidine protected the enzyme, and glutathione and catalase/superoxide dismutase did not, indicating covalent inactivation by a reactive metabolite. CYP3A4 was the main enzyme biotransforming notopterol. Entirely in vitro, but the numbers are in the range that predicts clinical interaction.

Hot-water decoctions and 40 percent ethanol infusions of umbelliferous crude drugs, including Qianghuo (Notopterygium incisum or N. forbesii), were tested against human CYP3A using microsomal testosterone 6beta-hydroxylation. All the umbelliferous drugs tested inhibited CYP3A to varying degrees, potency tracking hydrophobic (furanocoumarin) content, and several showed stronger inhibition after preincubation, indicating mechanism-based inhibition. Importantly, some formulated prescriptions inhibited more strongly than their furanocoumarin fractions alone, so constituents other than furanocoumarins contribute. In vitro microsomal work with no human dosing.

Notopterol, isolated from the rhizome of Notopterygium incisum, was given to mice with complete Freund's adjuvant-induced inflammatory arthritis. It reduced synovitis and joint swelling, raised mechanical pain thresholds, lowered IL-1beta, TNF-alpha and IFN-gamma and raised IL-4. In LPS-stimulated macrophages it restored mitochondrial function and shifted metabolism from glycolysis towards oxidative phosphorylation, driving M1 to M2 polarisation, with biophysical confirmation of high-affinity binding to the alpha-7 nicotinic acetylcholine receptor. This is single-constituent animal pharmacology and does not establish that the whole decocted herb behaves the same way.

Germplasm survey of wild-collected Notopterygium incisum combining phenotypic measurement with chemical assay. Notopterol ranged from 0.02 to 1.27 percent and isoimperatorin from 0.16 to 3.32 percent across individuals, allowing the plants to be split into high-, medium- and low-quality groups (isoimperatorin 2.38 versus 0.69 percent, notopterol 0.83 versus 0.33 percent at the extremes). The paper opens by noting that wild-collected Notopterygii Rhizoma et Radix faces resource depletion and unstable quality. For a prescriber the message is that authenticated species identity still does not guarantee potency: a 60-fold content range sits behind a single crude-drug name.

The most recent comprehensive review of the drug, covering botany, classical use, phytochemistry, analytical methods, pharmacology and pharmacokinetics. It confirms coumarins as the dominant non-volatile class and notopterol and isoimperatorin as the 2020 Chinese Pharmacopoeia quality markers. It is a narrative synthesis of preclinical and analytical literature: it does not identify controlled human trials of Notopterygii Rhizoma et Radix as a single herb, which remains the central gap in the evidence for this drug.

Review of the ethnopharmacology, constituents, analgesic, anti-inflammatory, anticancer and antioxidant pharmacology and analytical chemistry of Notopterygium incisum specifically, as distinct from the genus. Its own conclusion is the useful one for a clinical reference: more work is needed on pharmacokinetics and toxicology before the herb's clinical use and quality control can be put on a firm footing. No human efficacy trials of the single herb are identified.